Rheuma und chronisch-entzündliche Darmerkrankungen

B. Bokemeyer; H.-J. Lakomek

doi:10.1055/s-0038-1636987

Arthritis und Rheuma, Table of Contents

Arthritis und Rheuma 2018; 38(01): 22-26
DOI: 10.1055/s-0038-1636987

Organbeteiligung bei Rheuma

Schattauer GmbH

Rheuma und chronisch-entzündliche Darmerkrankungen

Rheumatism and inflammatory bowel diseases (IBD)

B. Bokemeyer

¹Gastroenterologische Gemeinschaftspraxis Minden

,

H.-J. Lakomek

²Klinik für Rheumatologie und Universitätsklinik für Geriatrie, Johannes Wesling Klinikum Minden

› Author Affiliations

Abstract

Zusammenfassung

Spondyloarthritiden unterteilen sich hinsichtlich der Skelettmanifestation in eine periphere und axiale Form und finden sich bei Morbus Crohn und Colitis ulcerosa in ca. 25 % der Fälle als extraintestinale Manifestation. Die Diagnostik beruht auf typischen klinischen Merkmalen bei der axialen Spondyloarthritis. Hier findet sich ein tiefer entzündlicher Rückenschmerz und eine Sakroiliitis (konventionell-radiologisch oder mittels MRT nachgewiesen). Die Diagnose der peripheren Beteiligung bei Spondyloarthritis richtet sich nach dem klinischen Bild unter Berücksichtigung von Krankheitsmerkmalen wie Arthritis, Enthesitis und Daktylitis. Im Vordergrund der Therapie der Spondyloarthritiden mit chronisch- entzündlicher Darmerkrankung (CED) steht neben der intensiven Physiotherapie die kurzfristige Gabe von nichtsteroidalen Antirheumatika (NSAR), da bei längerer Einnahme von NSAR Schübe der CED ausgelöst werden können. Cox-2-Hemmer können hier eine Alternative zu den herkömmlichen NSAR darstellen. Bei der axialen Spondyloarthritis sind Sulfasalazin und MTX weniger wirksam, weshalb möglichst früh eine Therapie mit Biologika gestartet werden sollte. Bei der Spondyloarthritis mit einer peripheren Arthritis können initial kurzfristig verabreichte orale Kortikosteroide effektiv sein, bei persistierender Arthritis kann eine Behandlung mit Sulfasalazin oder Methotrexat versucht werden. Auch für diese Verlaufsformen der Spondylo - arthritis gilt, bei therapieresistenten Fällen möglichst frühzeitig Biologika einzusetzen.

Summary

Both peripheral and axial arthropathies, which belong to the spondyloarthritis (SpA) group of conditions, occur as extra-intestinal manifestations (EIM) of Crohn’s disease (CD) and ulcerative colitis (UC) in 25 % of the cases. Diagnosis of axial SpA is based on typical clinical features such as inflammatory low back pain and sacroiliitis evidenced by magnetic resonance- or conventional radiographic imaging. Diagnosis of peripheral arthropathy is based on clinical signs of arthritis, enthesitis or dactylitis. Therapy of spondyloarthritis associated with IBD focusses on an intense physical therapy and a short-term application of non-steroidal antiinflammatory drugs (NSAIDs). As the longterm use of NSAID may trigger an exacerbation of IBD Coxibs represent an appropriate alternative. Sulfasalazine and methotrexate are of limited efficacy in the treatment of axial spondyloarthritis, so that the administration of suitable biologicals should be initiated as early as possible. Short-term oral corticosteroids can be effective in the treatment of a peripheral spondyloarthritis, in persistent arthritis a sulfasalazine- or methotrexate- therapy can be considered a promising option. The early use of biologicals is recommended in all cases resistant to the conventional therapeutic approach.

Schlüsselwörter

Chronisch-entzündliche Darmerkrankungen - Spondyloarthritis - extraintestinale Manifestationen - Colitis ulcerosa - M. Crohn

Keywords

Inflammatory bowel disease - spondyloarthritis - extra-intestinal manifestations - ulcerative colitis - Crohn´s disease

Full Text

References

Literatur
1 Baraliakos X, Braun J. Biologic therapies for spondyloarthritis: what is new?. Current rheumatology reports 2012; 14: 422-427.
2 Bolten W. Rheuma und Magen-Darm-Trakt. 1996; 93: A-380.
3 Bonner GF, Fakhri A, Vennamaneni SR. A longterm cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflammatory bowel diseases 2004; 10: 751-757.
4 Bourikas LA, Papadakis KA. Musculoskeletal manifestations of inflammatory bowel disease. Inflammatory bowel diseases 2009; 15: 1915-1924.
5 Cipolla G, Crema F, Sacco S. et al. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacological research: the official journal of the Italian Pharmacological Society 2002; 46: 1-6.
6 de Vlam K, Mielants H, Cuvelier C. et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. The Journal of rheumatology 2000; 27: 2860-2865.
7 De Vos M, Mielants H, Cuvelier C. et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996; 110: 1696-1703.
8 El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. The American journal of gastroenterology 2006; 101: 311-317.
9 Felder JB, Korelitz BI, Rajapakse R. et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. The American journal of gastroenterology 2000; 95: 1949-1954.
10 Fernando VelosoTavarela. Extraintestinal manifestations of inflammatory bowel disease: Do they influence treatment and outcome?. World J Gastroenterol 2011; 17: 2702-2707.
11 Ferraz MB, Tugwell P, Goldsmith CH, Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. The Journal of rheumatology 1990; 17: 1482-1486.
12 Fiehn C, Herzer P, Holle J. et al. Klug entscheiden in der Rheumatologie. Dt Ärztebl. 2016 113. (24).
13 Fornaciari G, Salvarani C, Beltrami M. et al. Muscoloskeletal manifestations in inflammatory bowel disease. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2001; 15: 399-403.
14 Generini S, Giacomelli R, Fedi R. et al. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Annals of the rheumatic diseases 2004; 63: 1664-1669.
15 Harbord M, Annese V, Vavricka SR. European Crohn’s and Colitis Organisation. et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis 2016; 10: 239-254.
16 Herfarth H, Obermeier F, Andus T. et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn’s disease. The American journal of gastroenterology 2002; 97: 2688-2690.
17 Jostins L, Ripke S, Weersma RK. et al. Hostmicrobe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124.
18 Kavanaugh A, Puig L, Gottlieb AB. PSUMMIT 1 Study Group. et al. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. Arthritis Care Res (Hoboken) 2015; 67: 1739-1749.
19 Lakatos L, Pandur T, David G. et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003; 09: 2300-2307.
20 Marzo-Ortega H, McGonagle D, O’Connor P, Emery P. Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Annals of the rheumatic diseases 2003; 62: 74-76.
21 McInnes KAIB, 1 Gottlieb AB, Puig L. PSUMMIT 1 Study Group. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 31: 780-789.
22 Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42: 387-391.
23 Orlando A, Orlando R, Ciccia F. et al. Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. Ann Rheum Dis 2017; 76: e31 doi: 10.1136/annrheumdis-2016–211011. Epub 2017 Jan 17.
24 Ossum AM, Palm Ø, Lunder AK. et al. IBSEN study group. J Crohns Colitis. 2017; 13 doi 10.1093/ecco-jcc/jjx126.
25 Palm Ø, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). The Journal of rheumatology 2002; 29: 511-515.
26 Peeters H, Vander Cruyssen B, Mielants H. et al. Clinical and genetic factors associated with sacroiliitis in Crohn’s disease. Journal of gastroenterology and hepatology 2008; 23: 132-137.
27 Poddubnyy D, Rudwaleit M, Haibel H. et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Annals of the rheumatic diseases 2012; 71: 1616-1622.
28 Queiro R, Maiz O, Intxausti J. et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clinical rheumatology 2000; 19: 445-449.
29 Reveille JD. Genetics of spondyloarthritis beyond the MHC. Nature reviews. Rheumatology 2012; 08: 296-303.
30 Ritchlin C, Rahman P, Kavanaugh A. PSUMMIT 2 Study Group. et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, doubleblind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73: 990-999.
31 Rudwaleit M, van der Heijde D, Landewé R. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Annals of the rheumatic diseases 2009; 68: 777-783.
32 Rudwaleit M, Van der Heijde D, Landewé R. et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70: 25-31.
33 S3-Leitlinie “Diagnostik und Therapie des Morbus Crohn” 2014. AWMF-Register-Nr.: 021/004.
34 Salvarani C, Vlachonikolis IG, van der Heijde DM. European Collaborative IBD Study Group. et al. Musculoskeletal manifestations in a populationbased cohort of inflammatory bowel disease patients. Scandinavian journal of gastroenterology 2001; 36: 1307-1313.
35 Sandborn WJ, Stenson WF, Brynskov J. et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006; 04: 203-211.
36 Steer S, Jones H, Hibbert J. et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. The Journal of rheumatology 2003; 30: 518-522.
37 Van den Bosch F, Kruithof E, De Vos M. et al. Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821-1822.
38 Vavricka SR, Rogler G, Gantenbein C. et al. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis 2015; 21: 1794-1800.
39 Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Annals of the rheumatic diseases 2006; 65: 423-432.